Board of SMS Pharmaceuticals approves JV with Chemo Group (Europe)

At meeting held on 27 September 2017

The Board of SMS Pharmaceuticals has approved in principle the proposal for the joint venture to be entered between the Company and CHEMO Group (Europe). The joint venture company will be formed in Switzerland to identify, evaluate, develop, scale up, undertake regulatory filings of Drug Master Files for the developed APIs under this proposed agreement in all major markets and commercially sell these products. The Intellectual Property will remain with the proposed JV Company while SMS Pharma gets revenue from the contract development and contact manufacturing of these products. The proposed JV Company will have a shareholding pattern as 55:45 between CHEMO Group and SMS Pharma respectively.

Powered by Capital Market - Live News